Company news
Outlook Therapeutics, Inc. news in 2025
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
December 31, 2025
Outlook Therapeutics Announces New Employment Inducement Grants
December 26, 2025
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
December 19, 2025
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
November 13, 2025
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
November 3, 2025
Outlook Therapeutics Provides Update on Type A Meeting with FDA
September 29, 2025
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
September 3, 2025
Outlook Therapeutics Requests Type A Meeting with FDA
September 2, 2025
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
August 14, 2025
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
July 24, 2025
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
July 1, 2025
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
June 18, 2025
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
June 10, 2025
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
June 2, 2025
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
May 23, 2025
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
May 22, 2025
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
May 15, 2025
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
April 7, 2025
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
February 28, 2025
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
February 13, 2025
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
February 3, 2025
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
January 30, 2025
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
January 22, 2025
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
January 21, 2025
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
January 15, 2025
Decks in 2025
- Technical Presentation (January 2025)
Technical · 13 slides · January 2025